IV thrombolysis in very severe and severe ischemic stroke

Neurology

Volumn 85, Issue 24, 2015, Pages 2098-2106

  Mazya, Michael V ^a   Lees, Kennedy R ^b   Collas, David ^c   Rand, Viiu Marika ^d   Mikulik, Robert ^e   Toni, Danilo ^f   Wahlgren, Nils ^a   Ahmed, Niaz ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b WATFORD GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d North Estonia Medical Centre   (Estonia)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CAUSE OF DEATH; CIRCULATION; CLINICAL FEATURE; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PERCUTANEOUS THROMBECTOMY; PRIORITY JOURNAL; REGISTER; STROKE PATIENT; INTERNATIONAL COOPERATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PROCEDURES; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERNATIONALITY; MALE; MIDDLE AGED; REGISTRIES; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84951304469     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002199     Document Type: Article

References (22)

1. IST-3 Collaborative Group, Sandercock P, Wardlaw JM, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2012; 379:2352-2363.
2. Mishra NK, Davis SM, Kaste M, Lees KR. Comparison of outcomes following thrombolytic therapy among patients with prior stroke and diabetes in the Virtual International Stroke Trials Archive (VISTA). Diabetes Care 2010;33: 2531-2537.
3. Mazya MV, Lees KR, Markus R, et al. Safety of intravenous thrombolysis for ischemic stroke in patients treated with warfarin. Ann Neurol 2013;74:266-274.
4. EMEA, Committee for Proprietary Medicinal Products. Summary information on a referral opinion following an arbitration pursuant to article 29 of directive 2001/83/EC, for Actilyse. 2002. Available at: http://www.ema.europa. eu/docs/en-GB/document-library/Referrals-document/Actilyse-29/WC500010327.pdf. Accessed May 30, 2015.
5. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274: 1017-1025.
6. Hacke W, Kaste M, Fieschi C, et al. Randomised doubleblind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245-1251.
7. Mishra NK, Lyden P, Grotta JC, Lees KR. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010;41:2612-2617.
8. Wahlgren N, Ahmed N, Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke 2008;39:3316-3322.
9. Whiteley WN, Slot KB, Fernandes P, Sandercock P, Wardlaw J. Risk factors for intracranial hemorrhage in acute ischemic stroke patients treated with recombinant tissue plasminogen activator: a systematic review and meta-analysis of 55 studies. Stroke 2012;43:2904-2909.
10. Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: Safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke 2012;43:1524-1531.
11. Ahmed N, Wahlgren N, Grond M, et al. Implementation and outcome of thrombolysis with alteplase 3-4.5 h after an acute stroke: an updated analysis from SITS-ISTR. Lancet Neurol 2010;9:866-874.
12. Wahlgren N, Ahmed N, Davalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-282.
13. Brown LD, Cai TT, DasGupta A. Interval estimation for a binomial proportion. Stat Sci 2001;16:101-133.
14. Mazya MV, Bovi P, Castillo J, et al. External validation of the SEDAN score for prediction of intracerebral hemorrhage in stroke thrombolysis. Stroke 2013;44:1595-1600.
15. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013;309: 2480-2488.
16. Ahmed N, Kellert L, Lees KR, Mikulik R, Tatlisumak T, Toni D. Results of intravenous thrombolysis within 4.5 to 6 hours and updated results within 3 to 4.5 hours of onset of acute ischemic stroke recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR): an observational study. JAMA Neurol 2013;70:837-844.
17. Pagola J, Ribo M, Alvarez-Sabin J, et al. Thrombolysis in anterior versus posterior circulation strokes: timing of recanalization, ischemic tolerance, and other differences. J Neuroimaging 2011;21:108-112.
18. Sarikaya H, Arnold M, Engelter ST, et al. Outcomes of intravenous thrombolysis in posterior versus anterior circulation stroke. Stroke 2011;42:2498-2502.
19. Sung SF, Chen CH, Chen YW, Tseng MC, Shen HC, Lin HJ. Predicting symptomatic intracerebral hemorrhage after intravenous thrombolysis: stroke territory as a potential pitfall. J Neurol Sci 2013;335:96-100.
20. Schonewille WJ, Wijman CA, Michel P, et al. Treatment and outcomes of acute basilar artery occlusion in the Basilar Artery International Cooperation Study (BASICS): a prospective registry study. Lancet Neurol 2009;8: 724-730.
21. Ford GA, Ahmed N, Azevedo E, et al. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010;41:2568-2574.
22. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-1935.